Use of the Charlson Comorbidity Index (CCI) appears to be beneficial for assessing prognosis and optimizing therapy in patients with advanced renal cell carcinoma who are receiving first-line sunitinib or pazopanib, suggests a recent study.
Pembrolizumab has demonstrated efficacy and acceptable safety in patients with recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) in the single-arm phase II KEYNOTE-629 trial, leading to US FDA approval for its use in patients with R/M cSCC not curable by surgery or radiation therapy.
Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.
Denosumab bests zoledronic acid at preventing skeletal-related events in vulnerable cancer patients, according to the results of a meta-analysis. The former also shows a better tolerability profile despite being associated with potential yet manageable adverse events.
De-escalating the BEACOPPescalated* regimen through a PET-driven strategy may reduce the risk of acute premature ovarian insufficiency (POI) in women with newly diagnosed advanced Hodgkin lymphoma (HL), subanalysis results of the phase III AHL2011 trial have shown.
Among patients with cancer who develop COVID-19, progressive disease and a higher ECOG* performance status (PS) are tied to an increased risk of mortality, according to early results ascertained from the COVID-19 and Cancer Consortium (CCC19) registry.
At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.